Parkinson's Disease, Psychotic Disorders
Conditions
Brief summary
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US sites. The maximum study duration will be 10 weeks. Subjects will have the option of continuing in an open-label extension study.
Detailed description
Parkinson's Disease is a progressive neurodegenerative disorder characterized by bradykinesia, rigidity, tremor and abnormal posture and gait. Many patients can have mild to moderate symptoms, while others with advanced disease have symptoms which interfere with activities of daily living to a severe degree. Although effective in addressing motor dysfunction, long-term use of anti-Parkinsonian agents has been implicated as a component in the development of psychiatric side effects including psychosis. Treatment of psychosis with typical antipsychotics is not recommended in this patient population, since even low potency typical antipsychotics can cause marked exacerbations of parkinsonism in Parkinson's disease patients. The use of atypical antipsychotics (e.g., clozapine, risperidone and quetiapine) has shown some efficacy in the treatment of psychosis in PD patients. Melperone is classified atypical antipsychotic. European experience with melperone spans more than 30 years, and it encompasses an established antipsychotic efficacy profile in the treatment of confusion, anxiety, unrest (particularly in the elderly) and schizophrenia as well as a favorable safety and tolerability profile. Eligible subjects with Parkinson's disease psychosis will participate in a 1-2 week Screening/Washout Period, a 5 week Titration Phase (one of three doses of melperone or placebo), a 1 week Maintenance Phase and a Taper/Follow-up Period up to 2 weeks. Following the Day 43 assessment, subjects may be given the option of receiving melperone in an open-label extension study.
Interventions
DRUGMelperone HCl
20 mg/day. Strength of melperone syrup is 5 mg/mL
DRUGPlacebo
Syrup formulation
Sponsors
Lundbeck LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The subject or subject's legally authorized representative (LAR) must sign and date the IRB/IEC approved Informed Consent Form and HIPAA Authorization (applicable to US sites only) prior to study participation. * Male or female subjects. If female: * Subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with a method of birth control acceptable to the investigator during the study, for at least one month prior to randomization and for one month following completion of the study. * Subject is not breastfeeding * Subjects of childbearing potential must have a negative serum pregnancy test at the screening visit and on Day 1. * Subjects with a clinical diagnosis of idiopathic Parkinson's Disease, defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features: * Rest tremor * Rigidity * Bradykinesia and/or akinesia * Postural and gait abnormalities * Subjects with psychosis: * Presence of visual and/or auditory hallucinations, with or without delusions, occurring during the four weeks prior to the screening visit. * Symptoms severe enough to clinically warrant treatment with an antipsychotic agent. * A Hallucinations or Delusions total item score (frequency x severity) of \> 4 on the Neuropsychiatric Inventory (NPI). * Subjects currently being treated with an antipsychotic agent who have not had visual and/or auditory hallucinations, with or without delusions, during the four weeks prior to screening, and/or have a Hallucinations or Delusions total item score \<4 on the NPI at the screening visit may be washed out (for 7 days or 5 half-lives, whichever is longer) and return for a repeat screening visit. The NPI Hallucinations or Delusions total item score must be ≥4 at the repeat visit to be considered for study entry. * Subject is on a stable dose of anti-Parkinsonian medication(s) for at least 7 days or 5 half-lives, whichever is longer, prior to the screening visit and is expected to remain on a stable dose for the duration of the study. * Subject is willing and able to comply with all study procedures.
Exclusion criteria
* Subject has any systemic factor contributing to the psychosis such as urinary infection, liver disease, renal failure, anemia, infection or cancer. * Subject has a history of significant psychotic disorders prior to the diagnosis of Parkinson's Disease, including but not limited to schizophrenia or bipolar disorder. * Subject has Dementia with Lewy-bodies (DLB). * Subject has dementia or a major depressive disorder precluding accurate assessment on rating scales. * Subject has an acute depressive episode at the time of the screening visit. * A score on the Mini-Mental State Examination (MMSE) of \< 21. * Subject has had a dose adjustment of their antidepressant medication within 30 days prior to the screening visit, or dose adjustments are planned during the duration of the trial. * Subject has had dose adjustments of an anxiolytic, cognitive enhancer, or other psychotropic medication (excluding antipsychotics) within 30 days prior to screening or dose adjustments are planned during the duration of the trial. * Subject has received depot antipsychotic agents within the past 3 months. * Subject has previously failed treatment with clozaril for psychosis in Parkinson's disease. Subjects who discontinued clozaril due to intolerability may be enrolled. * Subject has used any investigational product within 30 days or 5 half-lives, whichever is longer, prior to screening. * Subject cannot tolerate a wash-out of antipsychotic medication prior to randomization. * Subject has a history of a serious respiratory, gastrointestinal, renal, hematologic or other medical disorder. * Subject has a history of a serious cardiovascular condition (including, but not limited to, Class IV angina or Class IV heart failure) and/or a history of risk factors for Torsade de pointes (Tdp) (including but not limited to current treatment for hypokalemia or family history of long QT syndrome). * Subject had myocardial infarction within 6 months prior to screening. * Subject has a screening ECG with corrected QT interval by Bazett's correction formula (QTcB) of greater than 450 msec, if female, or 430 msec, if male. * Subject requires treatment with an α-agonist agent. * Subject has uncontrolled seizures, uncontrolled angina, or uncontrolled symptomatic orthostatic hypotension (or orthostatic hypotension leading to a history of falls 3 months prior to screening), or other medical disorders which would make the subject a poor candidate for a clinical trial. * Subject has a history of severe adverse reactions to antipsychotic medications and/or quinine. * Subject has clinically significant abnormal laboratory values, ECG, or findings on physical exam. * Subject has a recent history or current evidence of substance dependence or abuse. * Subject is unable to ingest liquid medication. * Subject is currently being treated with Deep Brain Stimulation (DBS). Randomization Criteria * Subject has a Hallucinations or Delusions total item score (frequency x severity) of \> 4 on the NPI. * Female subjects of childbearing potential must have a negative serum pregnancy test. * Subject has remained on a stable dose of anti-Parkinsonian medications. * Subject has not had a dose adjustment in their antidepressant medication since the screening visit. * Subjects have been washed out of previous antipsychotic agents for 5 half-lives or 7 days, whichever is longer, after the last dose of medication. * Subject has not had dose adjustments in an anxiolytic, cognitive enhancer or other psychotropic medication (excluding antipsychotics) since the Screening Visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient Evaluation of Symptoms of Psychosis. | 6 weeks (from Baseline to end of Maintenance Period) | The change in the Scale for Assessment of Positive Symptoms (SAPS) total score. The SAPS total score ranges from 0 to 170, with higher scores indicating more severe psychosis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Investigator/Caregiver Evaluations of Motor Function | 6 weeks (from Baseline to end of Maintenance Period) | The change in the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS III - motor exam) score. Scores on the UPDRS III - motor exam range from 0 to 108, with higher scores indicating more severe motor symptoms. |
Countries
India, Italy, United States
Participant flow
Recruitment details
Subjects were recruited from July 2005 to December 2007. Investigator sites were hospitals, research centers, movement disorder centers, and neurology centers.
Pre-assignment details
Subjects entered the Screening/Washout Period (for all previous antipsychotic medications) for a maximum of 2 weeks. On Day 1, the criteria for Randomization were reviewed by the investigator and psychiatric, motor function, and safety assessments were performed. Subjects who qualified on Day 1 were randomized to receive melperone or placebo.
Participants by arm
| Arm | Count |
|---|---|
| Melperone HCl - 20 mg 5 mg/mL Melperone syrup orally QHS | 15 |
| Melperone HCl - 40 mg 5 mg/mL Melperone syrup orally QHS | 19 |
| Melperone HCl - 60 mg 5 mg/mL Melperone syrup orally QHS | 25 |
| Placebo Syrup with 0.3 mg/mL quinine orally QHS | 30 |
| Total | 89 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 3 | 2 |
| Overall Study | Lack of Efficacy | 0 | 0 | 0 | 1 |
| Overall Study | Sponsor decision-pt moved to assist care | 0 | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 2 | 3 | 1 | 1 |
Baseline characteristics
| Characteristic | Melperone HCl - 20 mg | Melperone HCl - 40 mg | Melperone HCl - 60 mg | Placebo | Total |
|---|---|---|---|---|---|
| Age Continuous | 68.9 years STANDARD_DEVIATION 6.2 | 69.0 years STANDARD_DEVIATION 11.8 | 67.4 years STANDARD_DEVIATION 11.2 | 68.5 years STANDARD_DEVIATION 9.6 | 68.4 years STANDARD_DEVIATION 10 |
| Sex: Female, Male Female | 4 Participants | 6 Participants | 10 Participants | 10 Participants | 30 Participants |
| Sex: Female, Male Male | 11 Participants | 13 Participants | 15 Participants | 20 Participants | 59 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 6 / 15 | 8 / 19 | 10 / 25 | 6 / 30 |
| serious Total, serious adverse events | 2 / 15 | 2 / 19 | 2 / 25 | 0 / 30 |
Outcome results
Primary
Patient Evaluation of Symptoms of Psychosis.
The change in the Scale for Assessment of Positive Symptoms (SAPS) total score. The SAPS total score ranges from 0 to 170, with higher scores indicating more severe psychosis.
Time frame: 6 weeks (from Baseline to end of Maintenance Period)
Population: All randomized subjects who provided informed consent, took at least 1 dose of study drug, and had at least 1 post-baseline efficacy measurement (modified intent-to-treat \[MITT\] population) were included in the analysis of efficacy.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Melperone HCl - 20 mg | Patient Evaluation of Symptoms of Psychosis. | -9.8 Scores on a scale | Standard Error 4.4 |
| Melperone HCl - 40 mg | Patient Evaluation of Symptoms of Psychosis. | -12.9 Scores on a scale | Standard Error 4 |
| Melperone HCl - 60 mg | Patient Evaluation of Symptoms of Psychosis. | -9.7 Scores on a scale | Standard Error 3.5 |
| Placebo | Patient Evaluation of Symptoms of Psychosis. | -10.0 Scores on a scale | Standard Error 3.7 |
Comparison: The null hypothesis for each endpoint is that each melperone dose has the same mean as placebo; the alternative hypothesis is that at least one dose is more efficacious than placebo. Only subjects with both a baseline and Day 43 (end of Maintenance Phase) value are included.p-value: 0.517795% CI: [-6.3, 6.6]ANCOVA
Comparison: The null hypothesis for each endpoint is that each melperone dose has the same mean as placebo; the alternative hypothesis hypothesis is that at least one dose is more efficacious than placebo. Only subjects with both a baseline and Day 43 (end of Maintenance Phase) value are included.p-value: 0.151995% CI: [-8.5, 2.7]ANCOVA
Comparison: The null hypothesis for each endpoint is that each melperone dose has the same mean as placebo; the alternative hypothesis is that at least one dose is more efficacious than placebo. Only subjects with both a baseline and Day 43 (end of Maintenance Phase) value are included.p-value: 0.540695% CI: [-5.2, 5.8]ANCOVA
Secondary
Investigator/Caregiver Evaluations of Motor Function
The change in the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS III - motor exam) score. Scores on the UPDRS III - motor exam range from 0 to 108, with higher scores indicating more severe motor symptoms.
Time frame: 6 weeks (from Baseline to end of Maintenance Period)
Population: All randomized subjects who provided informed consent, took at least 1 dose of study drug, and had at least 1 post-baseline efficacy measurement (modified intent-to-treat \[MITT\] population) were included in the analysis of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Melperone HCl - 20 mg | Investigator/Caregiver Evaluations of Motor Function | 0.7 Scores on a scale | Standard Deviation 8.5 |
| Melperone HCl - 40 mg | Investigator/Caregiver Evaluations of Motor Function | 1.8 Scores on a scale | Standard Deviation 12.9 |
| Melperone HCl - 60 mg | Investigator/Caregiver Evaluations of Motor Function | 0.9 Scores on a scale | Standard Deviation 11.1 |
| Placebo | Investigator/Caregiver Evaluations of Motor Function | 0.5 Scores on a scale | Standard Deviation 6.4 |
Comparison: Only subjects with both a baseline and a post-baseline value are included.p-value: 0.9212ANCOVA